“R2M provided expert small molecule discovery, characterization and optimization support to our biologics-focused team in pursuit of a potent inhibitor of a novel intracellular target. Throughout, R2M's performance was stellar, and was more in keeping with what you would expect from a partner than a contractor. R2M would be my first stop for any med chem projects in the future.”

Taylor Schreiber M.D., Ph.D.
Chief Executive Officer

Shattuck Labs, Inc.